Discovery and evaluation of a non-Zn chelating, selective matrix metalloproteinase 13 (MMP-13) inhibitor for potential intra-articular treatment of osteoarthritis

…, B Bao, H Bluhm, J Boer, BM Gallagher Jr…

Index: Gege, Christian; Bao, Bagna; Bluhm, Harald; Boer, Juergen; Gallagher, Brian M.; Korniski, Brian; Powers, Timothy S.; Steeneck, Christoph; Taveras, Arthur G.; Baragi, Vijaykumar M. Journal of Medicinal Chemistry, 2012 , vol. 55, # 2 p. 709 - 716

Full Text: HTML

Citation Number: 29

Abstract

Osteoarthritis (OA) is a nonsystemic disease for which no oral or parenteral disease- modifying osteoarthritic drug (DMOAD) is currently available. Matrix metalloproteinase 13 (MMP-13) has attracted attention as a target with disease-modifying potential because of its major role in tissue destruction associated with OA. Being localized to one or a few joints, OA is amenable to intra-articular (IA) therapy, which has distinct advantages over oral ...